These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 22183643)

  • 21. Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma.
    Burnichon N; Buffet A; Parfait B; Letouzé E; Laurendeau I; Loriot C; Pasmant E; Abermil N; Valeyrie-Allanore L; Bertherat J; Amar L; Vidaud D; Favier J; Gimenez-Roqueplo AP
    Hum Mol Genet; 2012 Dec; 21(26):5397-405. PubMed ID: 22962301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era.
    Pillai S; Gopalan V; Smith RA; Lam AK
    Crit Rev Oncol Hematol; 2016 Apr; 100():190-208. PubMed ID: 26839173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies.
    Nölting S; Grossman AB
    Endocr Pathol; 2012 Mar; 23(1):21-33. PubMed ID: 22391976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Familial pheochromocytomas and paragangliomas.
    King KS; Pacak K
    Mol Cell Endocrinol; 2014 Apr; 386(1-2):92-100. PubMed ID: 23933153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET.
    Rischke HC; Benz MR; Wild D; Mix M; Dumont RA; Campbell D; Seufert J; Wiech T; Rössler J; Weber WA; Neumann HP
    J Nucl Med; 2012 Sep; 53(9):1352-8. PubMed ID: 22836345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular markers of paragangliomas/pheochromocytomas.
    Zhikrivetskaya SO; Snezhkina AV; Zaretsky AR; Alekseev BY; Pokrovsky AV; Golovyuk AL; Melnikova NV; Stepanov OA; Kalinin DV; Moskalev AA; Krasnov GS; Dmitriev AA; Kudryavtseva AV
    Oncotarget; 2017 Apr; 8(15):25756-25782. PubMed ID: 28187001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies.
    Santarpia L; Habra MA; Jiménez C
    Horm Metab Res; 2009 Sep; 41(9):680-6. PubMed ID: 19343618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Guide to Pheochromocytomas and Paragangliomas.
    Guilmette J; Sadow PM
    Surg Pathol Clin; 2019 Dec; 12(4):951-965. PubMed ID: 31672301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic and Molecular Biomarkers in Aggressive Pheochromocytomas and Paragangliomas.
    Torresan F; Iacobone C; Giorgino F; Iacobone M
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome.
    Salmenkivi K; Heikkilä P; Liu J; Haglund C; Arola J
    APMIS; 2003 Apr; 111(4):458-64. PubMed ID: 12780519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetics of pheochromocytomas and paragangliomas.
    Opocher G; Schiavi F
    Best Pract Res Clin Endocrinol Metab; 2010 Dec; 24(6):943-56. PubMed ID: 21115163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent Advances in Histopathological and Molecular Diagnosis in Pheochromocytoma and Paraganglioma: Challenges for Predicting Metastasis in Individual Patients.
    Yamazaki Y; Gao X; Pecori A; Nakamura Y; Tezuka Y; Omata K; Ono Y; Morimoto R; Satoh F; Sasano H
    Front Endocrinol (Lausanne); 2020; 11():587769. PubMed ID: 33193100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.
    Mete O; Asa SL; Gill AJ; Kimura N; de Krijger RR; Tischler A
    Endocr Pathol; 2022 Mar; 33(1):90-114. PubMed ID: 35285002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overexpression of the natural antisense hypoxia-inducible factor-1alpha transcript is associated with malignant pheochromocytoma/paraganglioma.
    Span PN; Rao JU; Oude Ophuis SB; Lenders JW; Sweep FC; Wesseling P; Kusters B; van Nederveen FH; de Krijger RR; Hermus AR; Timmers HJ
    Endocr Relat Cancer; 2011 Jun; 18(3):323-31. PubMed ID: 21422080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma.
    Buffet A; Burnichon N; Favier J; Gimenez-Roqueplo AP
    Best Pract Res Clin Endocrinol Metab; 2020 Mar; 34(2):101416. PubMed ID: 32295730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
    Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas.
    Bechmann N; Moskopp ML; Ullrich M; Calsina B; Wallace PW; Richter S; Friedemann M; Langton K; Fliedner SMJ; Timmers HJLM; Nölting S; Beuschlein F; Fassnacht M; Prejbisz A; Pacak K; Ghayee HK; Bornstein SR; Dieterich P; Pietzsch J; Wielockx B; Robledo M; Qin N; Eisenhofer G
    Endocr Relat Cancer; 2020 Nov; 27(11):625-640. PubMed ID: 33112842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors.
    Babic B; Patel D; Aufforth R; Assadipour Y; Sadowski SM; Quezado M; Nilubol N; Prodanov T; Pacak K; Kebebew E
    Surgery; 2017 Jan; 161(1):220-227. PubMed ID: 27865588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes.
    Gimenez-Roqueplo AP; Dahia PL; Robledo M
    Horm Metab Res; 2012 May; 44(5):328-33. PubMed ID: 22328163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genotype-specific abnormalities in mitochondrial function associate with distinct profiles of energy metabolism and catecholamine content in pheochromocytoma and paraganglioma.
    Rao JU; Engelke UF; Rodenburg RJ; Wevers RA; Pacak K; Eisenhofer G; Qin N; Kusters B; Goudswaard AG; Lenders JW; Hermus AR; Mensenkamp AR; Kunst HP; Sweep FC; Timmers HJ
    Clin Cancer Res; 2013 Jul; 19(14):3787-95. PubMed ID: 23723300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.